# Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

> **NCT07400965** · PHASE2 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 250 (estimated)

## Conditions studied

- Demodex Blepharitis

## Interventions

- **DRUG:** GLK-321 low dose BID
- **DRUG:** GLK-321 mid dose BID
- **DRUG:** GLK-321 high dose BID
- **DRUG:** GLK-321 high dose QD
- **DRUG:** Placebo BID

## Key facts

- **NCT ID:** NCT07400965
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400965, "Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07400965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*